Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00593918

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children — IIRI  

Respiratory Syncytial Virus Infection Clinical Trial

Official title:
Innate Immunity and RSV Infection in Children

Clinical Trial Summary

In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.

Clinical Trial Description

Infection with RSV is the most common cause of respiratory tract illnesses (LRIs) in the first 3 years of life. There are significant social and health care costs associated with RSV-LRIs. More than 3% of US children are hospitalized each year due to RSV and 500 die annually. Several longitudinal studies have also suggested that children who have RSV-LRIs are at substantially increased risk of developing asthma in the first 3 years after infection and bronchial hyperresponsiveness (BHR) many years after the primary infection. Mechanisms involved in RSV disease are not well understood. Recent reports suggest that RSV may initiate the innate immune response through the pattern recognition receptor, Toll like receptor-4 (TLR4). In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production. It has been suggested that such a mechanism may result in altered immune responses to RSV infection and different clinical outcomes. This research has direct application to improving our understanding of bronchiolitis in early childhood, particularly those factors that influence severity of the disease, and may have implications for possible therapy of patients with bronchiolitis in the future. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00593918
Study type Observational
Source University of Wisconsin, Madison
Contact
Status Completed
Phase N/A
Start date November 2003
Completion date June 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT02016690 - Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immuno Compromised Children With Synagis N/A
Completed NCT01107535 - Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection N/A
Completed NCT04491877 - Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers Phase 1/Phase 2
Completed NCT05987072 - A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults. Phase 1
Completed NCT01006629 - Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children Phase 2/Phase 3
Recruiting NCT06134648 - Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate Phase 1/Phase 2
Completed NCT03473002 - A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults Phase 1
Completed NCT02135614 - Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Phase 2
Completed NCT01909843 - ALX-0171 Safety Study in Adults With Hyperresponsive Airways Phase 1
Recruiting NCT06206720 - A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV Phase 2
Completed NCT02254421 - Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Phase 2
Recruiting NCT06237296 - Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older Phase 1
Completed NCT01537198 - Surveillance of Synagis in Korean Pediatric Patients N/A
Active, not recruiting NCT05687279 - Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA) Phase 1/Phase 2
Completed NCT01297504 - A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America N/A
Recruiting NCT06079320 - A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection Phase 2/Phase 3
Completed NCT06424795 - Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
Completed NCT02309320 - A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171 Phase 1/Phase 2
Recruiting NCT06194318 - First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults Phase 1
Completed NCT01466062 - Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Phase 3